Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
dystrophy, showing sustained stabilization of patient function over 3.5 years and a continued favorable safety profile. An unusually high 99% of eligible participants from prior sevasemten trials chose to enroll in MESA, underlining strong patient retention and interest in this potential first-in-class therapy for a disease with no approved treatments. We'll now examine how these long-term stabilization results for sevasemten in Becker muscular dystrophy shape Edgewise Therapeutics' overall investment narrative. We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. What Is Edgewise Therapeutics' Investment Narrative? To own Edgewise Therapeutics, you have to believe sevasemten can translate its promising Becker muscular dystrophy profile into an approved product despite a history of losses, no current revenue, and ongoing cash burn. The new 3.5-year MESA data strengthen the scientific story by showing durable funct
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.MarketBeat
- Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics (EWTX) was given a new $46.00 price target by Raymond James Financial, Inc..MarketBeat
EWTX
Earnings
- 2/26/26 - Miss
EWTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- EWTX's page on the SEC website